Clinical Trials Browser

OTHER × Interventional × Afatinib × Clear all

NCT06648096 2026-05-27

AFAN

Phase 1/2 Recruiting

Classical hematologyHead & Neck

Squamous Cell Carcinoma of Head and Neck, Fanconi Anemia

NCT06302621 2026-05-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06486142 2026-05-14

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07040956 2026-05-04

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05070403 2026-04-01

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Squamous Cell, Skin Neoplasms

NCT01783587 2026-03-25

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2 Completed

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Phase 1 Completed

Head and Neck Neoplasms

NCT06085755 2025-12-15

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Phase 1/2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06753747 2025-12-03

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT06897735 2025-11-18

EDDIS-a1

Phase 1 Not yet recruiting

DermatologicHead & NeckThoracic

Lung Neoplasms, Melanoma, Mouth Neoplasms

NCT04497584 2025-10-01

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Phase 2 Active not recruiting

Advanced Squamous Non Small Cell Lung Cancer

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT07010120 2025-06-13

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

Phase EARLY_PHASE1 Recruiting

Glioblastoma, Recurrence

NCT05298176 2025-03-28

COMBINATION

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05215548 2025-02-19

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Phase 2 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03083678 2025-02-13

Afatinib in Locally Advanced and Metastatic Chordoma

Phase 2 Completed

Chordoma

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06741982 2024-12-19

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT01553942 2024-11-20

Afatinib With CT and RT for EGFR-Mutant NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Phase 1 Completed

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04183712 2024-10-16

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Phase 2 Recruiting

Gastrointestinal

Gallbladder Neoplasms

NCT04839471 2024-07-08

BEAR

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04410653 2024-04-05

Afatinib in Advanced NRG1-Rearranged Malignancies

Phase 2 Completed

Neoplasm Metastasis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01542437 2024-02-06

NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02768337 2024-01-31

CamBMT1

Phase 1/2 Terminated

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02183883 2023-11-29

DARWIN1

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01522768 2023-11-01

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Phase 2 Completed

42 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02506517 2023-08-01

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Phase 2 Completed

Other solid neoplasm

Solid Tumors

NCT05865132 2023-05-18

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Phase 2 Unknown

PFS

NCT02501603 2023-01-27

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04201756 2022-12-23

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Phase 2 Completed

Adenocarcinoma of Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01320280 2022-07-01

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Phase 2 Terminated

Neoplasms, Prostatic Neoplasms

NCT03711422 2022-06-14

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms

NCT02451553 2022-06-07

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Phase 1 Completed

Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms

NCT03695510 2022-04-21

ALPHA

Phase 2 Completed

Head and Neck Neoplasms

NCT03054038 2022-04-14

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02423525 2022-03-10

Safety Study of Afatinib for Brain Cancer

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Meningioma, Oligodendroglioma, Meningeal Carcinomatosis

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms